Medifast Appoints Nicholas Johnson as CEO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Medifast "announced that its Board of Directors has formally appointed Nicholas Johnson as Chief Executive Officer, effective June 1, 2026. Johnson will succeed Dan Chard as CEO, who will continue to serve as Chairman of the Board. The appointment follows the leadership transition plan that the company disclosed in January and reflects the Board's confidence in Johnson's leadership and the company's strategic direction. Chard will remain actively engaged as Chairman of the Board, supporting Johnson and the leadership team while continuing to provide strategic oversight."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MED?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MED
About MED
Medifast, Inc. is a health and wellness company. The Company is engaged in offering habit-based and coach-guided lifestyle solution, OPTAVIA. It sells a variety of weight loss, weight management and healthy living products all based on its proprietary formulas under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE categories. Its product line includes approximately 74 consumable options, including, but not limited to, bars, cereal, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. Its OPTAVIA ASCEND mini meals deliver nutrition that gives clients’ bodies what they need to - whether losing weight on a GLP-1 medication or in weight management mode. Its OPTAVIA Fuelings contain approximately 24 vitamins and minerals, high quality, complete protein, and no colors, flavors or sweeteners from artificial sources.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Major U.S. Indices Mixed as Zscaler Shares Decline Amid Guidance Concerns
- Market Performance: On Tuesday, major Wall Street indices finished mixed as investors assessed the potential for a resolution in the U.S.-Iran conflict, with the blue-chip Dow down 0.2%, the S&P 500 up 0.6%, and the tech-heavy Nasdaq Composite leading with a 1.2% gain.
- Zscaler Earnings: Zscaler's shares fell in after-hours trading despite reporting better-than-expected third-quarter results, with an adjusted EPS of $1.08 and revenue rising 25% year-over-year to $850.5 million; however, mixed guidance overshadowed these results, leading to investor disappointment.
- Medifast Leadership Change: Medifast appointed Nicholas Johnson as CEO effective June 1, 2026, succeeding Dan Chard, who will remain as chairman of the board; this leadership transition could impact the company's strategic direction and market performance moving forward.
- Firefly Aerospace Contract: Firefly Aerospace was awarded a $75 million subcontract from NASA's Jet Propulsion Laboratory to deliver four drones for NASA's MoonFall mission, although shares fell about 5% at the time of the announcement, this contract could support future business growth for the company.
See More
Medifast Appoints New CEO Nicholas Johnson Effective June 2026
- Executive Change: Medifast has appointed Nicholas Johnson as CEO effective June 1, 2026, succeeding current CEO Dan Chard, who will remain as chairman of the board, ensuring continuity and stability in corporate governance.
- Strategic Revenue Outlook: The company reaffirms its revenue outlook for 2026 at $270 million to $300 million, indicating growth potential in the coming years, particularly with profitability improvement plans set to begin in Q4 2026 aimed at enhancing overall financial performance.
- Cost Reduction Initiative: Medifast is implementing a $30 million cost-cutting plan designed to optimize operational efficiency and enhance profitability, a move that will help the company maintain its competitive edge in a challenging market.
- Positive Market Reaction: Despite weak Q1 performance, Medifast's stock has surged, reflecting investor confidence in the company's future strategy and leadership changes, which may attract more investor interest.
See More
OPTAVIA Sets New Standards in Weight Loss Industry
- Market Size: The global weight loss industry is projected to reach $16.3 billion by 2025, yet the uneven peer-reviewed clinical validation across programs highlights a critical need for scientific backing in the sector.
- Clinical Research Support: OPTAVIA's clinical approach is backed by 18 randomized controlled trials and over 30 scientific studies, ensuring the effectiveness and scientific credibility of its weight loss programs, thereby enhancing trust among consumers and healthcare professionals.
- Importance of Coaching Support: Research indicates that clients using the OPTAVIA program with coaching support lose an average of 10 times more weight and 17 times more fat than those without, underscoring the crucial role of personalized guidance in the weight loss journey.
- Focus on Metabolic Health: As the market floods with weight loss solutions, OPTAVIA emphasizes the importance of metabolic health through scientific research, shifting the industry's focus from mere weight loss to body composition and long-term health management.
See More
Medifast Q1 Earnings Beat Expectations, Shares Surge 18%
- Significant Stock Surge: Medifast shares jumped nearly 18% on Tuesday, rising from $10.63 to approximately $12.63, significantly outperforming the S&P 500's 15.13% one-day gain, reflecting market optimism about the company's future potential.
- Weak Financial Performance: Despite Q1 revenue falling 34.3% year-over-year to $76 million, primarily due to a 44.9% drop in active coaches to 14,000, the average revenue per active coach increased by 19.2% to $5,432, indicating improved productivity among the remaining coaches.
- Effective Cost Control: The company's gross profit declined 38.6% to $51.8 million in Q1, yet SG&A expenses fell by 35.6%, demonstrating the effectiveness of its cost-cutting measures, with expectations of generating over $30 million in future savings.
- Positive Future Outlook: Although the net loss widened to $2.1 million (or $0.19 per share), the company ended the quarter with $168.9 million in cash and no debt, with management stating that they have realigned their cost structure effectively and plan to launch a new metabolic health system in July, which could further fuel stock price increases.
See More
Medifast Q1 2026 Earnings Call Insights and Outlook
- Initial Revenue Growth: Medifast reported Q1 2026 revenue of $76 million, a 34.3% year-over-year decline, yet marked the first sequential revenue growth in three years, indicating early signs of business stabilization that could lay the groundwork for future market recovery.
- Declining Coach Numbers: The number of active earning coaches fell to approximately 14,000, down 44.9% year-over-year; however, the average revenue per coach increased by 19.2% to $5,432, suggesting progress in enhancing coach productivity despite the overall decline.
- Cost Structure Optimization: The company anticipates generating over $30 million in future savings through a realignment of its cost structure, which not only helps address market realities but may also facilitate a return to profitability starting in Q4 2026, thereby strengthening financial health.
- New Product Line Launch: Medifast plans to unveil a new comprehensive metabolic system at its coach convention in July, with management reiterating that this product launch will be crucial for restoring profitability, expected to drive sustained earnings growth into 2027 and beyond.
See More
Medifast (MED) to Announce Q1 Earnings on May 4th
- Earnings Announcement Schedule: Medifast (MED) is set to release its Q1 2023 earnings report on May 4th after market close, with consensus EPS estimate at -$0.52 and revenue estimate at $69.2 million, reflecting a 40.2% year-over-year decline.
- Historical Performance: Over the past two years, Medifast has exceeded EPS estimates 88% of the time and revenue estimates 88% of the time, indicating a degree of stability in its financial performance despite current challenges.
- Expectation Adjustments: In the last three months, there have been no upward revisions to EPS estimates, with one downward revision, while revenue estimates also saw no upward revisions and one downward revision, suggesting market caution regarding future performance.
- Future Revenue Targets: Medifast has outlined a revenue target of $270 million to $300 million for 2026, indicating the company's commitment to driving execution amid CEO transition and a focus on metabolic health for long-term growth.
See More
Major U.S. Indices Mixed as Zscaler Shares Decline Amid Guidance Concerns
- Market Performance: On Tuesday, major Wall Street indices finished mixed as investors assessed the potential for a resolution in the U.S.-Iran conflict, with the blue-chip Dow down 0.2%, the S&P 500 up 0.6%, and the tech-heavy Nasdaq Composite leading with a 1.2% gain.
- Zscaler Earnings: Zscaler's shares fell in after-hours trading despite reporting better-than-expected third-quarter results, with an adjusted EPS of $1.08 and revenue rising 25% year-over-year to $850.5 million; however, mixed guidance overshadowed these results, leading to investor disappointment.
- Medifast Leadership Change: Medifast appointed Nicholas Johnson as CEO effective June 1, 2026, succeeding Dan Chard, who will remain as chairman of the board; this leadership transition could impact the company's strategic direction and market performance moving forward.
- Firefly Aerospace Contract: Firefly Aerospace was awarded a $75 million subcontract from NASA's Jet Propulsion Laboratory to deliver four drones for NASA's MoonFall mission, although shares fell about 5% at the time of the announcement, this contract could support future business growth for the company.
See More
Medifast Appoints New CEO Nicholas Johnson Effective June 2026
- Executive Change: Medifast has appointed Nicholas Johnson as CEO effective June 1, 2026, succeeding current CEO Dan Chard, who will remain as chairman of the board, ensuring continuity and stability in corporate governance.
- Strategic Revenue Outlook: The company reaffirms its revenue outlook for 2026 at $270 million to $300 million, indicating growth potential in the coming years, particularly with profitability improvement plans set to begin in Q4 2026 aimed at enhancing overall financial performance.
- Cost Reduction Initiative: Medifast is implementing a $30 million cost-cutting plan designed to optimize operational efficiency and enhance profitability, a move that will help the company maintain its competitive edge in a challenging market.
- Positive Market Reaction: Despite weak Q1 performance, Medifast's stock has surged, reflecting investor confidence in the company's future strategy and leadership changes, which may attract more investor interest.
See More
OPTAVIA Sets New Standards in Weight Loss Industry
- Market Size: The global weight loss industry is projected to reach $16.3 billion by 2025, yet the uneven peer-reviewed clinical validation across programs highlights a critical need for scientific backing in the sector.
- Clinical Research Support: OPTAVIA's clinical approach is backed by 18 randomized controlled trials and over 30 scientific studies, ensuring the effectiveness and scientific credibility of its weight loss programs, thereby enhancing trust among consumers and healthcare professionals.
- Importance of Coaching Support: Research indicates that clients using the OPTAVIA program with coaching support lose an average of 10 times more weight and 17 times more fat than those without, underscoring the crucial role of personalized guidance in the weight loss journey.
- Focus on Metabolic Health: As the market floods with weight loss solutions, OPTAVIA emphasizes the importance of metabolic health through scientific research, shifting the industry's focus from mere weight loss to body composition and long-term health management.
See More
Medifast Q1 Earnings Beat Expectations, Shares Surge 18%
- Significant Stock Surge: Medifast shares jumped nearly 18% on Tuesday, rising from $10.63 to approximately $12.63, significantly outperforming the S&P 500's 15.13% one-day gain, reflecting market optimism about the company's future potential.
- Weak Financial Performance: Despite Q1 revenue falling 34.3% year-over-year to $76 million, primarily due to a 44.9% drop in active coaches to 14,000, the average revenue per active coach increased by 19.2% to $5,432, indicating improved productivity among the remaining coaches.
- Effective Cost Control: The company's gross profit declined 38.6% to $51.8 million in Q1, yet SG&A expenses fell by 35.6%, demonstrating the effectiveness of its cost-cutting measures, with expectations of generating over $30 million in future savings.
- Positive Future Outlook: Although the net loss widened to $2.1 million (or $0.19 per share), the company ended the quarter with $168.9 million in cash and no debt, with management stating that they have realigned their cost structure effectively and plan to launch a new metabolic health system in July, which could further fuel stock price increases.
See More
Medifast Q1 2026 Earnings Call Insights and Outlook
- Initial Revenue Growth: Medifast reported Q1 2026 revenue of $76 million, a 34.3% year-over-year decline, yet marked the first sequential revenue growth in three years, indicating early signs of business stabilization that could lay the groundwork for future market recovery.
- Declining Coach Numbers: The number of active earning coaches fell to approximately 14,000, down 44.9% year-over-year; however, the average revenue per coach increased by 19.2% to $5,432, suggesting progress in enhancing coach productivity despite the overall decline.
- Cost Structure Optimization: The company anticipates generating over $30 million in future savings through a realignment of its cost structure, which not only helps address market realities but may also facilitate a return to profitability starting in Q4 2026, thereby strengthening financial health.
- New Product Line Launch: Medifast plans to unveil a new comprehensive metabolic system at its coach convention in July, with management reiterating that this product launch will be crucial for restoring profitability, expected to drive sustained earnings growth into 2027 and beyond.
See More
Medifast (MED) to Announce Q1 Earnings on May 4th
- Earnings Announcement Schedule: Medifast (MED) is set to release its Q1 2023 earnings report on May 4th after market close, with consensus EPS estimate at -$0.52 and revenue estimate at $69.2 million, reflecting a 40.2% year-over-year decline.
- Historical Performance: Over the past two years, Medifast has exceeded EPS estimates 88% of the time and revenue estimates 88% of the time, indicating a degree of stability in its financial performance despite current challenges.
- Expectation Adjustments: In the last three months, there have been no upward revisions to EPS estimates, with one downward revision, while revenue estimates also saw no upward revisions and one downward revision, suggesting market caution regarding future performance.
- Future Revenue Targets: Medifast has outlined a revenue target of $270 million to $300 million for 2026, indicating the company's commitment to driving execution amid CEO transition and a focus on metabolic health for long-term growth.
See More
